This article is more than 5 years old. Information may no longer be current.
Oscar R. Benavente, MD, on preliminary cognitive results from the SPS3 trial
Click Here to Manage Email Alerts
SAN DIEGO — In this video, Oscar R. Benavente, MD, professor of neurology at the University of British Columbia in Vancouver, Canada, discusses the cognitive results of the SPS3 trial, which he presented at the International Stroke Conference.
The trial included 3,020 patients who experienced lacunar stroke, randomly assigned in a double blind fashion to receive either aspirin with clopidogrel or aspirin alone. Patients were also randomly assigned a target systolic BP of either 130 mmHg to 149 mmHg, or a more intensive goal of below 130 mm Hg. The primary results of the study had been published earlier; Benavente presented new, preliminary results from intention-to-treat analysis related specifically to cognitive function.
He noted that SPS3 is the first study to provide detailed cognitive assessment among patients with cerebrovascular disease. A mild decrease in cognitive function was observed at the end of the study, but function did not differ between groups according to BP control or the antiplatelet agent administered.
Benavente added that the cohort had a relatively young mean age of 62 years, and that the patients likely did not have sufficient time to develop cognitive impairment following stroke. Future analysis, he said, will include subgroup analysis of patients that showed a greater degree of cognitive decline.